Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants

This publication has 16 references indexed in Scilit:

• Neonatal Host Defense against Staphylococcal Infections
  Journal of Immunology Research, 2013
• Protection Against Staphylococcus aureus by Antibody to the Polyglycerolphosphate Backbone of Heterologous Lipoteichoic Acid
  The Journal of Infectious Diseases, 2012
• Treatment of Neonatal Sepsis with Intravenous Immune Globulin
  New England Journal of Medicine, 2011
• A Randomized Study of a Monoclonal Antibody (Pagibaximab) to Prevent Staphylococcal Sepsis
  Pediatrics, 2011
• Neonatal Outcomes of Extremely Preterm Infants From the NICHD Neonatal Research Network
  Pediatrics, 2010
• Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight Neonates
  Antimicrobial Agents and Chemotherapy, 2009
• Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults
  International Immunopharmacology, 2009
• Clinical Trial of Safety and Efficacy of IHN-A21 for the Prevention of Nosocomial Staphylococcal Bloodstream Infection in Premature Infants
  The Journal of Pediatrics, 2007
• A Controlled Trial of Intravenous Immune Globulin to Reduce Nosocomial Infections in Very-Low-Birth-Weight Infants
  New England Journal of Medicine, 1994
• Prevention of Necrotizing Enterocolitis in Low-Birth-Weight Infants by IgA–IgG Feeding
  New England Journal of Medicine, 1988